These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 16553541)

  • 1. Fluoxetine 40-60 mg versus fluoxetine 20 mg in the treatment of children and adolescents with a less-than-complete response to nine-week treatment with fluoxetine 10-20 mg: a pilot study.
    Heiligenstein JH; Hoog SL; Wagner KD; Findling RL; Galil N; Kaplan S; Busner J; Nilsson ME; Brown EB; Jacobson JG
    J Child Adolesc Psychopharmacol; 2006; 16(1-2):207-17. PubMed ID: 16553541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous administration of adenosine triphosphate and phosphocreatine combined with fluoxetine in major depressive disorder: protocol for a randomized, double-blind, placebo-controlled pilot study.
    Chen Y; Cao X; Zang W; Tan S; Ou CQ; Shen X; Gao T; Zhao L
    Trials; 2019 Jan; 20(1):34. PubMed ID: 30626424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Problem-solving ability and comorbid personality disorders in depressed outpatients.
    Harley R; Petersen T; Scalia M; Papakostas GI; Farabaugh A; Fava M
    Depress Anxiety; 2006; 23(8):496-501. PubMed ID: 16845662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluoxetine once every third day in the treatment of major depressive disorder.
    Tural U; Onder E
    Eur Arch Psychiatry Clin Neurosci; 2003 Dec; 253(6):307-12. PubMed ID: 14714120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of mirtazapine and fluoxetine in the treatment of major depressive disorder: a double-blind, randomized trial.
    Amini H; Aghayan S; Jalili SA; Akhondzadeh S; Yahyazadeh O; Pakravan-Nejad M
    J Clin Pharm Ther; 2005 Apr; 30(2):133-8. PubMed ID: 15811165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Double-blind comparison of bupropion and fluoxetine in depressed outpatients.
    Feighner JP; Gardner EA; Johnston JA; Batey SR; Khayrallah MA; Ascher JA; Lineberry CG
    J Clin Psychiatry; 1991 Aug; 52(8):329-35. PubMed ID: 1907963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching to reboxetine: an efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetine.
    Fava M; McGrath PJ; Sheu WP;
    J Clin Psychopharmacol; 2003 Aug; 23(4):365-9. PubMed ID: 12920412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment-related adverse events and outcome in a clinical trial of fluoxetine for major depressive disorder.
    Papakostas GI; Petersen T; Denninger JW; Montoya HD; Nierenberg AA; Alpert JE; Fava M
    Ann Clin Psychiatry; 2003; 15(3-4):187-92. PubMed ID: 14971864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of fluoxetine remission for hospitalized patients with major depressive disorder.
    Lin CH; Lane HY; Chen CC; Juo SH; Yen CF
    Psychiatry Clin Neurosci; 2011 Aug; 65(5):510-7. PubMed ID: 21851460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hopelessness as a predictor of non-response to fluoxetine in major depressive disorder.
    Papakostas GI; Petersen T; Homberger CH; Green CH; Smith J; Alpert JE; Fava M
    Ann Clin Psychiatry; 2007; 19(1):5-8. PubMed ID: 17453655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term sertraline treatment of children and adolescents with major depressive disorder.
    Rynn M; Wagner KD; Donnelly C; Ambrosini P; Wohlberg CJ; Landau P; Yang R
    J Child Adolesc Psychopharmacol; 2006; 16(1-2):103-16. PubMed ID: 16553532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of medical comorbidity on acute treatment in major depressive disorder.
    Iosifescu DV; Nierenberg AA; Alpert JE; Smith M; Bitran S; Dording C; Fava M
    Am J Psychiatry; 2003 Dec; 160(12):2122-7. PubMed ID: 14638581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of subchronic treatment with fluoxetine for major depressive disorder in children and adolescents.
    Nilsson M; Joliat MJ; Miner CM; Brown EB; Heiligenstein JH
    J Child Adolesc Psychopharmacol; 2004; 14(3):412-7. PubMed ID: 15650497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
    Wohlreich MM; Mallinckrodt CH; Prakash A; Watkin JG; Carter WP
    Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of mirtazapine in treating major depressive disorder with anxiety symptoms: an 8-week open-label randomised paroxetine-controlled trial.
    Kim JE; Yoon SJ; Kim J; Jung JY; Jeong HS; Cho HB; Shin E; Lyoo IK; Kim TS
    Int J Clin Pract; 2011 Mar; 65(3):323-9. PubMed ID: 21314870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Fluoxetine: relations between plasma concentration and therapeutic effects in 32 patients with major depression and treated with 20 mg/day].
    Bourdeaux R; Pannetier P; Younos C; Desor D; Lehr PR; Capolaghi B
    Encephale; 1998; 24(1):57-61. PubMed ID: 9559305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder.
    Colonna L; Andersen HF; Reines EH
    Curr Med Res Opin; 2005 Oct; 21(10):1659-68. PubMed ID: 16238906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of patient expectancy in placebo and nocebo effects in antidepressant trials.
    Rutherford BR; Wall MM; Glass A; Stewart JW
    J Clin Psychiatry; 2014 Oct; 75(10):1040-6. PubMed ID: 25006812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluoxetine in depressed patients on dialysis.
    Blumenfield M; Levy NB; Spinowitz B; Charytan C; Beasley CM; Dubey AK; Solomon RJ; Todd R; Goodman A; Bergstrom RF
    Int J Psychiatry Med; 1997; 27(1):71-80. PubMed ID: 9565715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.